BPC-157 vs AOD-9604
Reviewed by the BestHealingPeptides Editorial Team ·
Both BPC-157 and AOD-9604 are discussed in the context of post-injury recovery, but they originate from very different research programmes and target different tissues.
BPC-157
A 15-amino-acid pentadecapeptide derived from a protective protein found in human gastric juice. The most-studied healing research peptide, with extensive pre-clinical work on tendon, ligament, gut, and vascular repair.
AOD-9604
A 16-amino-acid C-terminal analogue of human growth hormone, originally investigated for lipolytic activity without IGF-1 effects, and subsequently studied for cartilage repair and post-injury recovery.
| Aspect | BPC-157 | AOD-9604 |
|---|---|---|
| Origin | Gastric-juice-derived pentadecapeptide (15 aa) | hGH C-terminal fragment (177-191, 16 aa) |
| Hormonal axis | Hormone-independent | No IGF-1 elevation observed in trials |
| Primary tissue focus | Tendon, ligament, gut | Cartilage (intra-articular models); adipose (original obesity programme) |
| Clinical trial history | None published | Phase IIb obesity trials completed |
| WADA category | S0 | Case-by-case; broad S2 interpretation has been applied |
| MHRA status | Not licensed | Not licensed |
Origin and design
BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid pentadecapeptide derived from the sequence of a naturally occurring gastric-juice protein — the compound was originally isolated from gastric juice as a putative gastric-protective factor and subsequently characterised as a synthetic-peptide research tool by the Sikiric Zagreb group. AOD-9604 is a 16-amino-acid synthetic peptide corresponding to the C-terminal 177-191 fragment of human growth hormone with an additional N-terminal tyrosine. It was developed by Metabolic Pharmaceuticals in Australia as an anti-obesity agent designed to preserve the lipolytic activity of the hGH C-terminal domain while eliminating the IGF-1-elevating and insulin-desensitising activities of the full-length hormone.
Tissue focus and mechanism
BPC-157's strongest pre-clinical evidence is in tendon, ligament, and gastrointestinal repair. Its mechanism involves VEGFR2-Akt-eNOS-driven angiogenesis, nitric-oxide-system stabilisation, and growth-hormone-receptor upregulation on tenocytes and fibroblasts. AOD-9604's original characterisation focused on lipolysis via β3-adrenergic receptor sensitisation, driving glycerol release from differentiated 3T3-L1 adipocytes without measurable IGF-1 elevation. More recent research interest has extended to cartilage repair, particularly intra-articular delivery in surgically induced rabbit knee osteoarthritis models where AOD-9604 combined with hyaluronic acid produced improved OARSI histological scores and safranin-O proteoglycan retention vs hyaluronic acid alone.
Hormonal axis and safety differentials
AOD-9604 is reported to lack growth-hormone-receptor-mediated effects on IGF-1 elevation — confirmed across Phase I and Phase IIb human obesity trials (Heffernan et al., J Clin Endocrinol Metab, 2001) — which distinguishes it from full-length human growth hormone and from the GHRH-analogue and GHRP-class secretagogues that engage the GH/IGF-1 axis directly. This is a mechanistically important safety feature: theoretical oncogenic and insulin-resistance concerns from chronic IGF-1 elevation do not apply. BPC-157 is similarly hormone-axis-independent, acting on the NO system and tissue-specific receptors without engaging the GH/IGF-1 axis peripherally.
Regulatory and anti-doping
Neither peptide is licensed as a medicine by the MHRA in the UK. AOD-9604 completed Phase IIb obesity clinical trials (~250 subjects) without progressing to registration; BPC-157 has not entered registered clinical trials for any indication. BPC-157 falls under WADA S0 (Non-Approved Substances) as a pharmacologically active substance without marketing authorisation. AOD-9604's WADA status is complex — it is not explicitly named on the Prohibited List, but WADA's S2 category (Peptide Hormones, Growth Factors, Related Substances and Mimetics) has been argued to encompass growth-hormone C-terminal fragments and analogues. Athletes should seek specific guidance from their national anti-doping body before any research use in populations subject to testing.
Choosing between them
For tendon, ligament, gut, and general soft-tissue repair research, BPC-157 has the deeper evidence base with decades of dedicated pre-clinical characterisation across multiple injury models. For cartilage-focused research — particularly osteoarthritis and joint-injury models — AOD-9604 is more mechanistically apt, especially in combination with hyaluronic acid delivery vehicles that leverage the intra-articular chondrocyte data. The two peptides address different research questions rather than competing for the same use case; combination protocols have not been meaningfully characterised.
Verdict
For tendon and ligament research, BPC-157 has the deeper pre-clinical evidence base. AOD-9604 remains interesting in cartilage-focused research, particularly intra-articular delivery in combination with hyaluronic acid in surgically-induced osteoarthritis models. The compounds address different research questions with mechanistically distinct pharmacology; head-to-head is really a two-pronged research choice rather than a competition for the same use case.
Where to source research peptides for laboratory research
The following UK-based suppliers stock research-grade, lyophilised peptides for in-vitro and pre-clinical work. Purity and provenance vary; always request a Certificate of Analysis (CoA) and confirm cold-chain storage on arrival. None of the products linked below are approved for human use.
- PeptideAuthority.co.uk
UK-based research peptide supplier with batch certificates of analysis and >99% purity testing.
- PeptideBarn.co.uk
Wide catalogue of research-grade lyophilised peptides shipped from the UK, including bulk vials.